



Biocon Limited

20th KM Hosur Road
Electronics City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423
CIN : L24234KA1978PLC003417

www.biocon.com

No: 2017/SEC/AUG/105

August 30, 2017

National Stock Exchange of India
Limited
"Exchange Plaza", 5th Floor,
Plot No. C/1, G Block,
Bandra-Kurla Complex
Bandra (East), Mumbai – 400051

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400001

NSE - Symbol - BIOCON

BSE - Scrip code - 532523

Dear Sir,

Sub: USFDA Target Action Date for Trastuzumab reset to December 3, 2017.

Please find below the Company's statement on the subject matter.

"The US FDA has notified our partner Mylan that they will extend the target action date for their Trastuzumab 351(k) application to Dec 3, 2017 in order to review some of the clarificatory information submitted to them as a part of the application review process. This three month extension has no impact on the anticipated timetable for commercialization of this product in the U.S." -**Company Spokesperson**

Kindly take on record the same.

Thanking You,

Yours faithfully,
For **BIOCON LIMITED**


Rajiv Balakrishnan
Company Secretary

